US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

XILIO THERAPEUTICS, INC.

0.8100

-0.0050-0.61%

Post-market: 0.83440.0244+3.01%18:12 EDT

Volume:248.12K

Turnover:207.75K

Market Cap:41.94M

PE:-0.74

High:0.8600

Open:0.8305

Low:0.8001

Close:0.8150

Loading ...

Overview Company News Filings

Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs

Abbvie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies

THOMSON REUTERS

Abbvie Inc - Collaboration to Develop Masked T-Cell Engagers

THOMSON REUTERS

Abbvie Inc - Xilio to Receive $52 Million Upfront, Eligible for up to $2.1 Billion

THOMSON REUTERS

Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Xilio Therapeutics Phase 2 Study of Vilastobart Plus Atezolizumab Demonstrates 27% Response Rate in Colorectal Cancer

MT Newswires Live

Xilio Therapeutics Advances with Phase 2 Trial Data

Xilio reports results from ongoing Phase 2 clinical trial of vilastobart

Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (Xtx101), a Tumor-Activated Anti-Ctla-4, in Combination With Atezolizumab in Patients With Metastatic Microsatellite Stable Colorectal Cancer

THOMSON REUTERS

Xilio Therapeutics Inc - 27% Response Rate in Mss Crc Patients Without Liver Metastases

THOMSON REUTERS

Xilio Therapeutics Inc - Low Incidence of Immune-Related Adverse Events Reported

THOMSON REUTERS

BRIEF-Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS

Press Release: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI

Xilio Therapeutics appoints Caroline Hensley as CLO

Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

THOMSON REUTERS

Press Release: Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer

After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright

Xilio Therapeutics Advances Cancer Drug and Financial Outlook

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/stock/XLO/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"XLO","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLO\",,,,,undefined,":{"symbol":"XLO","market":"US","secType":"STK","nameCN":"XILIO THERAPEUTICS, INC.","latestPrice":0.81,"timestamp":1745352000000,"preClose":0.815,"halted":0,"volume":248123,"hourTrading":{"tag":"盘后","latestPrice":0.8344,"preClose":0.81,"latestTime":"18:12 EDT","volume":16000,"amount":12967.2,"timestamp":1745359957617},"delay":0,"floatShares":21998119,"shares":51773717,"eps":-1.088384,"marketStatus":"Not Yet Opened","change":-0.005,"latestTime":"04-22 16:00:00 EDT","open":0.8305,"high":0.86,"low":0.8001,"amount":207745.2246533,"amplitude":0.073497,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.088384,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1745395200000},"marketStatusCode":0,"adr":0,"listingDate":1634875200000,"exchange":"NASDAQ","adjPreClose":0.815,"preHourTrading":{"tag":"盘前","latestPrice":0.8305,"preClose":0.814,"latestTime":"09:29 EDT","volume":87641,"amount":74683.07657569999,"timestamp":1745328598427},"postHourTrading":{"tag":"盘后","latestPrice":0.8344,"preClose":0.81,"latestTime":"18:12 EDT","volume":16000,"amount":12967.2,"timestamp":1745359957617},"volumeRatio":1.048289},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"XLO\",,,,,undefined,":{"symbol":"XLO","floatShares":21998119,"roa":"-56.48%","roe":"-214.02%","lyrEps":-1.088384,"volumeRatio":1.048289,"shares":51773717,"dividePrice":0,"high":0.86,"amplitude":0.073497,"preClose":0.815,"low":0.8001,"week52Low":0.62,"pbRate":"2.38","psRate":"6.61","week52High":1.7,"institutionHeld":0,"latestPrice":0.81,"eps":-1.088384,"divideRate":0,"volume":248123,"delay":0,"ttmEps":-1.088384,"open":0.8305,"prevYearClose":0.955,"prevWeekClose":0.7516,"prevMonthClose":0.7244,"prevQuarterClose":0.7244,"fiveDayClose":0.7144,"twentyDayClose":0.7857,"sixtyDayClose":0.8201},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"XLO\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2510376307","title":"Xilio Therapeutics Announces Multiple Masked T Cell Engager Programs","url":"https://stock-news.laohu8.com/highlight/detail?id=2510376307","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510376307?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:35","pubTimestamp":1739363700,"startTime":"0","endTime":"0","summary":"Also entered into collaboration and option agreement with AbbVie to develop novel tumor-activated immunotherapies, including masked T cell engagers, with $52.0 million in upfront payments. Extended anticipated cash runway into the first quarter of 2026. Company to host investor conference call and webcast today at 8:30 am ET. T cell engagers are designed to redirect immune effector cells against cancer cells by simultaneously binding to a specific tumor-associated antigen expressed on the cancer cells and the T cell receptor complex on T cells, resulting in T cell-mediated killing of tumor cells. To date, T cell engagers have demonstrated significant promise as cancer immunotherapies in a variety of advanced solid tumors, but their potential has been limited by toxicity.Xilio is leveraging its proprietary, clinically-validated tumor-activation platform to advance a pipeline of wholly-owned, novel masked T cell engager molecules with conditional half-life modulation designed to enable p","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xilio-therapeutics-announces-multiple-masked-123500894.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["LENZ","XLO","BK4139"],"gpt_icon":1},{"id":"2510937550","title":"Abbvie and Xilio Therapeutics Announce Collaboration and Option Agreement to Develop Novel Tumor-Activated Immunotherapies","url":"https://stock-news.laohu8.com/highlight/detail?id=2510937550","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510937550?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:30","pubTimestamp":1739363402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA2F338F:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU2347655156.SGD","LU1551013342.USD","LU0211328371.USD","LU1267930490.SGD","IE00B4R5TH58.HKD","LU0114720955.EUR","LU2237443465.HKD","LU2468319806.SGD","IE00B3PB1722.GBP","LU2237443978.SGD","LU0553294199.USD","LU2089283258.USD","LU0310799852.SGD","BK4588","LU2237443622.USD","LU0128525929.USD","LU0943347566.SGD","LU0965508806.USD","LU1244550221.USD","LU1551013425.SGD","LU1430594728.SGD","LU1585245621.USD","SG9999011175.SGD","LU0203345920.USD","BK4533","LU2089284900.SGD","XLO","LU0820561909.HKD","ABBV","LU0256863811.USD","LU1244550494.USD","LU1244550577.SGD","LU1291159041.SGD","LU1003077747.HKD","LU1732799900.SGD","IE00BVYPNW00.USD","LU0234570918.USD","LU0965509010.AUD","SG9999015952.SGD","LU1934455863.HKD","LU0545039389.USD","IE0002141913.USD","LU0965509101.SGD","LU0965509283.SGD","LU1839511570.USD","LU0456855351.SGD","LU1989772840.SGD","LU0708994859.HKD","IE00BJJMRZ35.SGD","LU0417517546.SGD"],"gpt_icon":0},{"id":"2510375578","title":"Abbvie Inc - Collaboration to Develop Masked T-Cell Engagers","url":"https://stock-news.laohu8.com/highlight/detail?id=2510375578","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510375578?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:30","pubTimestamp":1739363402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA2F338F:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["LU0553294199.USD","LU2237443622.USD","LU1291159041.SGD","IE00BVYPNW00.USD","LU1839511570.USD","IE00BJJMRZ35.SGD","LU0114720955.EUR","LU0203345920.USD","LU2347655156.SGD","LU1934455863.HKD","SG9999015952.SGD","IE0002141913.USD","LU1585245621.USD","LU0820561909.HKD","LU0417517546.SGD","LU0256863811.USD","LU0965509283.SGD","LU1551013342.USD","SG9999011175.SGD","LU2089284900.SGD","LU0456855351.SGD","LU2468319806.SGD","BK4533","LU0211328371.USD","LU1989772840.SGD","LU1430594728.SGD","ABBV","LU0708994859.HKD","LU1267930490.SGD","LU0965508806.USD","XLO","LU0310799852.SGD","LU0965509010.AUD","LU0965509101.SGD","LU2237443978.SGD","LU2237443465.HKD","LU1551013425.SGD","LU0943347566.SGD","IE00B4R5TH58.HKD","LU1244550577.SGD","LU1732799900.SGD","IE00B3PB1722.GBP","LU1244550221.USD","LU2089283258.USD","LU1003077747.HKD","LU0545039389.USD","LU0234570918.USD","LU0128525929.USD","BK4588","LU1244550494.USD"],"gpt_icon":0},{"id":"2510375570","title":"Abbvie Inc - Xilio to Receive $52 Million Upfront, Eligible for up to $2.1 Billion","url":"https://stock-news.laohu8.com/highlight/detail?id=2510375570","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510375570?lang=en_us&edition=fundamental","pubTime":"2025-02-12 20:30","pubTimestamp":1739363402,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250212:nTUA2F338F:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IE00BJJMRZ35.SGD","LU1291159041.SGD","LU1551013342.USD","LU1244550494.USD","IE00B4R5TH58.HKD","LU0456855351.SGD","LU2347655156.SGD","SG9999015952.SGD","LU0114720955.EUR","SG9999011175.SGD","LU0256863811.USD","LU2237443978.SGD","LU0708994859.HKD","LU0820561909.HKD","LU1244550221.USD","LU1244550577.SGD","LU0943347566.SGD","BK4588","IE00BVYPNW00.USD","LU0553294199.USD","LU0965509283.SGD","LU0234570918.USD","LU0310799852.SGD","LU0545039389.USD","LU1934455863.HKD","IE0002141913.USD","LU0417517546.SGD","LU1430594728.SGD","LU1839511570.USD","LU1585245621.USD","LU2089284900.SGD","LU2468319806.SGD","BK4533","ABBV","IE00B3PB1722.GBP","LU0128525929.USD","LU2237443465.HKD","LU2237443622.USD","XLO","LU1003077747.HKD","LU1267930490.SGD","LU0965509101.SGD","LU1732799900.SGD","LU0211328371.USD","LU2089283258.USD","LU0965508806.USD","LU0965509010.AUD","LU1551013425.SGD","LU0203345920.USD","LU1989772840.SGD"],"gpt_icon":0},{"id":"2508173920","title":"Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2508173920","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508173920?lang=en_us&edition=fundamental","pubTime":"2025-02-04 05:30","pubTimestamp":1738618200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250203:nTUABQ7X4T:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2505733081","title":"Xilio Therapeutics Phase 2 Study of Vilastobart Plus Atezolizumab Demonstrates 27% Response Rate in Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505733081","media":"MT Newswires Live","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505733081?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:42","pubTimestamp":1737499359,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics  said late Tuesday that initial data from a phase 2 study of vilastobart in combination with atezolizumab to treat metastatic microsatellite stable colorectal cancer showed a 27% preliminary response rate in patients without liver metastases.The drug combination also reduced levels of carcinoembryonic antigen and circulating tumor DNA along with improvement of symptoms, according to the company.The data shows differentiated safety and tolerability profile and low incidence of immune-related adverse events, Xilio added.Shares of Xilio Therapeutics were down more than 7% in recent after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","XLO"],"gpt_icon":0},{"id":"2505353057","title":"Xilio Therapeutics Advances with Phase 2 Trial Data","url":"https://stock-news.laohu8.com/highlight/detail?id=2505353057","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505353057?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:28","pubTimestamp":1737498531,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics ( ($XLO) ) just unveiled an update. On January 21, 2025, Xilio Therapeutics announced initial data from a Phase 2 clinical trial...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-advances-with-phase-2-trial-data?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-advances-with-phase-2-trial-data?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLO","BK4139","LENZ"],"gpt_icon":0},{"id":"2505733861","title":"Xilio reports results from ongoing Phase 2 clinical trial of vilastobart","url":"https://stock-news.laohu8.com/highlight/detail?id=2505733861","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505733861?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:10","pubTimestamp":1737497408,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced initial data from its ongoing Phase 2 clinical trial evaluating vilastobart, or XTX101, a tumor-activated, Fc-en...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-reports-results-from-ongoing-phase-2-clinical-trial-of-vilastobart?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-reports-results-from-ongoing-phase-2-clinical-trial-of-vilastobart?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2505780768","title":"Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (Xtx101), a Tumor-Activated Anti-Ctla-4, in Combination With Atezolizumab in Patients With Metastatic Microsatellite Stable Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2505780768","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505780768?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:05","pubTimestamp":1737497100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUABMK3YK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2505738851","title":"Xilio Therapeutics Inc - 27% Response Rate in Mss Crc Patients Without Liver Metastases","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738851","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738851?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:05","pubTimestamp":1737497100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUABMK3YK:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2505738813","title":"Xilio Therapeutics Inc - Low Incidence of Immune-Related Adverse Events Reported","url":"https://stock-news.laohu8.com/highlight/detail?id=2505738813","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505738813?lang=en_us&edition=fundamental","pubTime":"2025-01-22 06:05","pubTimestamp":1737497100,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250121:nTUABMK3YK:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XLO","BK4139"],"gpt_icon":0},{"id":"2502845869","title":"BRIEF-Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502845869","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502845869?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:33","pubTimestamp":1736548425,"startTime":"0","endTime":"0","summary":"Jan 10 (Reuters) - Xilio Therapeutics Inc   :   * XILIO THERAPEUTICS ANNOUNCES INDUCEMENT GRANT UNDER NASDAQ LISTING RULE 5635(C)(4)Source text:    Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1201861249.SGD","IE00B64PRP62.GBP","IE00BGHQF748.EUR","LU0106831901.USD","LU0128525689.USD","TSYW.SI","LU2125154935.USD","LU0310800965.SGD","LU0130102774.USD","QID","NQmain","LU0130517989.USD","LU1366192091.USD","LU0648001328.SGD","LU1791807156.HKD","USJW.SI","XLO","LU2417539215.USD","LU2210150020.SGD","LU2125154778.USD","MNQmain","NVIW.SI","PSQ","BK4207","LU2456880835.USD","LU0162691827.USD","LU2210149790.SGD","LU0477156953.USD",".IXIC","LU0072461881.USD","LU0320765646.SGD","LENZ","SQQQ","BK4588","TQQQ","BK4566","IE00BSNM7G36.USD","LU1267930227.SGD","LU2360032135.SGD","LU0052756011.USD","LU0098860793.USD","LU1162221912.USD","LU1668664300.SGD","USAW.SI","LU2236285917.USD","LU2095319765.USD","QLD","BK4112","NDAQ"],"gpt_icon":0},{"id":"2502133848","title":"Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502133848","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502133848?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:00","pubTimestamp":1736546400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250110:nTUA3JNTKK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2502848997","title":"Press Release: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)","url":"https://stock-news.laohu8.com/highlight/detail?id=2502848997","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2502848997?lang=en_us&edition=fundamental","pubTime":"2025-01-11 06:00","pubTimestamp":1736546400,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Jan. 10, 2025  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that, effective January 1, 2025, the company granted a non-qualified stock option to purchase 375,000 shares of its common stock to Caroline Hensley, its newly hired Chief Legal Officer, under Xilio Therapeutics' 2022 Inducement Stock Incentive Plan.The stock option is subject to the terms and conditions of Xilio Therapeutics' 2022 Inducement Stock Incentive Plan, as well as the terms and conditions of the stock option agreement covering the grant and were made as an inducement material to the individual entering into employment with the company in accordance with Nasdaq Listing Rule 5635.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","LENZ","LU2210150020.SGD","NDAQ","XLO","IE00BGHQF748.EUR","LU2210149790.SGD","BK4139","IE00B64PRP62.GBP","IE00BKPKM429.USD",".IXIC","IE00B3QW5Z07.USD","LU2095319765.USD","BK4112","NQmain","BK4588"],"gpt_icon":0},{"id":"2492012492","title":"Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO GI","url":"https://stock-news.laohu8.com/highlight/detail?id=2492012492","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492012492?lang=en_us&edition=fundamental","pubTime":"2024-12-19 20:30","pubTimestamp":1734611400,"startTime":"0","endTime":"0","summary":"Announces preliminary Phase 1 data for XTX301, a tumor-activated IL-12, demonstrating an improved tolerability profile over historical data for rhIL-12, with no dose-limiting toxicities. Completed additional private placement with Gilead for purchase of remaining equity investment in connection with XTX301 partnership. WALTHAM, Mass., Dec. 19, 2024  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced plans to present initial data from its ongoing Phase 2 trial for vilastobart , a tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4, in combination with atezolizumab  in patients with metastatic microsatellite stable colorectal cancer  at the ASCO Gastrointestinal  Cancers Symposium in San Francisco, California from January 23-25, 2025. In addition, today the company announced preliminary data from Phase 1 dose escalation for XTX301, an investiga","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/w3j6s6GyGXevQnSvYrKEMg--~B/aD0yODk7dz00NjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/w3j6s6GyGXevQnSvYrKEMg--~B/aD0yODk7dz00NjI7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/790a3773663b9c214f4e9c03501ad13e"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/xilio-therapeutics-present-initial-phase-123000443.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B12V2V27.USD","LU0359202008.SGD","TME","BK4531","01698","BK4108","BK4548","AST","BK4599","XLO","LU0359201612.USD","IE00BYQNZ168.SGD","LENZ","BK4535","BK4563","ALT","BK4565","BK4509","LU1023057109.AUD","LU1878469433.USD","LU2039709279.SGD","BK4139","SG9999011746.SGD","BK4526","IE00BYTNYN87.SGD","BK4552","BK4571"],"gpt_icon":0},{"id":"2491660068","title":"Xilio Therapeutics appoints Caroline Hensley as CLO","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660068","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660068?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:35","pubTimestamp":1734352533,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics (XLO) announced the appointment of Caroline Hensley as chief legal officer. Hensley most recently served as senior vice presiden...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-appoints-caroline-hensley-as-clo?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/xilio-therapeutics-appoints-caroline-hensley-as-clo?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["XLO","BK4139","LENZ"],"gpt_icon":0},{"id":"2491660149","title":"Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491660149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491660149?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:30","pubTimestamp":1734352200,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241216:nTUA7RPXRB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2491906660","title":"Press Release: Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer","url":"https://stock-news.laohu8.com/highlight/detail?id=2491906660","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2491906660?lang=en_us&edition=fundamental","pubTime":"2024-12-16 20:30","pubTimestamp":1734352200,"startTime":"0","endTime":"0","summary":"WALTHAM, Mass., Dec. 16, 2024  -- Xilio Therapeutics, Inc. , a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced the appointment of Caroline  Hensley as chief legal officer.\"Caroline is an accomplished lawyer and biotechnology executive who brings a wealth of experience advising public life science companies across all stages of development and commercialization,\" said René Russo, Pharm.D., president and chief executive officer of Xilio. \"Her expertise and strategic insights make her a tremendous addition to our executive team, and we are excited to have her onboard.\". \"I am thrilled to join the Xilio team at this pivotal moment in the company's growth and look forward to helping to advance Xilio's promising pipeline of novel, tumor-activated immuno-oncology therapies,\" said Ms. Hensley.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLO","LENZ","BK4139"],"gpt_icon":0},{"id":"2490070860","title":"After Golden Cross, Xilio Therapeutics, Inc. (XLO)'s Technical Outlook is Bright","url":"https://stock-news.laohu8.com/highlight/detail?id=2490070860","media":"Zacks","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2490070860?lang=en_us&edition=fundamental","pubTime":"2024-12-09 22:55","pubTimestamp":1733756102,"startTime":"0","endTime":"0","summary":"After reaching an important support level, Xilio Therapeutics, Inc.  could be a good stock pick from a technical perspective. XLO recently experienced a \"golden cross\" event, which saw its 50-day simple moving average breaking out above its 200-day simple moving average.A golden cross is a technical chart pattern that can signify a potential bullish breakout. It's formed from a crossover involving a security's short-term moving average breaking above a longer-term moving average, with the most common moving averages being the 50-day and the 200-day, since bigger time periods tend to form stronger breakouts.There are three stages to a golden cross. First, there must be a downtrend in a stock's price that eventually bottoms out. Then, the stock's shorter moving average crosses over its longer moving average, triggering a positive trend reversal. The third stage is when a stock continues the upward momentum to higher prices.A golden cross contrasts with a death cross, another widely-follo","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/OL7xfT5pzuzwP2wxb1pcSw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/OL7xfT5pzuzwP2wxb1pcSw--~B/aD02MjU7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/7ea641b46fe75c0a913349e5e610d6a2"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/golden-cross-xilio-therapeutics-inc-145502393.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4139","XLO"],"gpt_icon":0},{"id":"2481918195","title":"Xilio Therapeutics Advances Cancer Drug and Financial Outlook","url":"https://stock-news.laohu8.com/highlight/detail?id=2481918195","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481918195?lang=en_us&edition=fundamental","pubTime":"2024-11-07 22:49","pubTimestamp":1730990951,"startTime":"0","endTime":"0","summary":"Xilio Therapeutics ( ($XLO) ) has shared an announcement. Xilio Therapeutics announced significant progress in its pipeline and financial updates f...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-advances-cancer-drug-and-financial-outlook?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/xilio-therapeutics-advances-cancer-drug-and-financial-outlook?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","XLO"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":2,"totalSize":53,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/XLO\",params:#limit:5,,,undefined,":[{"market":"US","date":"2025-03-11","symbol":"XLO","fiscalQuarterEnding":"2024/12","expectedEps":-0.22,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1741665600000,"reportTimeType":"pre","actualEps":-0.2},{"market":"US","date":"2024-11-07","symbol":"XLO","fiscalQuarterEnding":"2024/09","expectedEps":-0.25,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1730955600000,"reportTimeType":"pre","actualEps":-0.22},{"market":"US","date":"2024-08-08","symbol":"XLO","fiscalQuarterEnding":"2024/06","expectedEps":-0.23,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1723089600000,"reportTimeType":"pre","actualEps":-0.24},{"market":"US","date":"2024-05-14","symbol":"XLO","fiscalQuarterEnding":"2024/03","expectedEps":-0.3,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1715659200000,"reportTimeType":"pre","actualEps":-0.59},{"market":"US","date":"2024-04-01","symbol":"XLO","fiscalQuarterEnding":"2023/12","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1711944000000,"reportTimeType":"post","actualEps":-0.64}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"XLO\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"XLO\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1671681600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/XLO\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"XLO","date":"2025-04-21","current":-0.66814,"percent":0.661972,"low":-8.819798,"twenty":-1.086672,"median":-0.795827,"eighty":-0.539795,"high":-0.169617,"avg":-1.30378,"sd":1.569746,"marketCap":38913125},"quantilePoints":[{"date":"2021-10-22","current":-5.619943,"twenty":-5.655644,"median":-5.655644,"eighty":-5.634223,"marketCap":423962880},{"date":"2021-10-29","current":-5.897428,"twenty":-5.742879,"median":-5.655644,"eighty":-5.632588,"marketCap":444896047},{"date":"2021-11-05","current":-7.534236,"twenty":-7.275719,"median":-5.778004,"eighty":-5.653191,"marketCap":568375236},{"date":"2021-11-12","current":-7.783621,"twenty":-8.139785,"median":-6.784325,"eighty":-5.655644,"marketCap":587188588},{"date":"2021-11-19","current":-7.994369,"twenty":-8.332268,"median":-7.783621,"eighty":-5.669463,"marketCap":603087196},{"date":"2021-11-26","current":-6.993317,"twenty":-8.285904,"median":-7.699322,"eighty":-5.707754,"marketCap":527568808},{"date":"2021-12-03","current":-4.59754,"twenty":-8.14962,"median":-7.070591,"eighty":-5.652373,"marketCap":353417461},{"date":"2021-12-10","current":-3.644608,"twenty":-8.092015,"median":-6.680707,"eighty":-5.383906,"marketCap":280164654},{"date":"2021-12-17","current":-3.769058,"twenty":-8.017551,"median":-5.735855,"eighty":-4.164453,"marketCap":289731252},{"date":"2021-12-23","current":-5.689144,"twenty":-8.011931,"median":-5.689668,"eighty":-4.138852,"marketCap":437330192},{"date":"2021-12-31","current":-5.689144,"twenty":-7.994369,"median":-5.689144,"eighty":-4.156631,"marketCap":437330192},{"date":"2022-01-07","current":-5.091784,"twenty":-7.797671,"median":-5.658171,"eighty":-4.266858,"marketCap":391410521},{"date":"2022-01-14","current":-5.162898,"twenty":-7.783621,"median":-5.653587,"eighty":-4.59754,"marketCap":396877149},{"date":"2022-01-21","current":-4.842884,"twenty":-7.716182,"median":-5.64292,"eighty":-4.788126,"marketCap":372277325},{"date":"2022-01-28","current":-4.77177,"twenty":-7.567253,"median":-5.591843,"eighty":-4.822972,"marketCap":366810698},{"date":"2022-02-04","current":-3.598384,"twenty":-7.225139,"median":-5.49358,"eighty":-4.4546,"marketCap":276611346},{"date":"2022-02-11","current":-4.739768,"twenty":-7.024227,"median":-5.32737,"eighty":-4.153075,"marketCap":364350716},{"date":"2022-02-18","current":-4.82155,"twenty":-6.909018,"median":-5.17001,"eighty":-4.244813,"marketCap":370637337},{"date":"2022-02-25","current":-4.675765,"twenty":-6.763601,"median":-5.152231,"eighty":-4.222767,"marketCap":359430751},{"date":"2022-03-04","current":-3.096766,"twenty":-6.21074,"median":-5.107785,"eighty":-4.106851,"marketCap":234734857},{"date":"2022-03-11","current":-2.663652,"twenty":-5.825774,"median":-5.088228,"eighty":-3.781858,"marketCap":201904807},{"date":"2022-03-18","current":-2.77554,"twenty":-5.735355,"median":-5.013559,"eighty":-3.685854,"marketCap":210385903},{"date":"2022-03-25","current":-2.526499,"twenty":-5.698992,"median":-4.963778,"eighty":-3.539359,"marketCap":191508625},{"date":"2022-04-01","current":-2.475969,"twenty":-5.691597,"median":-4.880219,"eighty":-3.443152,"marketCap":187678452},{"date":"2022-04-08","current":-2.537327,"twenty":-5.689563,"median":-4.835772,"eighty":-3.159567,"marketCap":192329376},{"date":"2022-04-14","current":-2.180008,"twenty":-5.689144,"median":-4.77177,"eighty":-2.747387,"marketCap":165244585},{"date":"2022-04-22","current":-1.454542,"twenty":-5.689144,"median":-4.707766,"eighty":-2.648493,"marketCap":110254251},{"date":"2022-04-29","current":-1.27492,"twenty":-5.677766,"median":-4.57265,"eighty":-2.569089,"marketCap":96638949},{"date":"2022-05-06","current":-1.311037,"twenty":-5.658676,"median":-4.385974,"eighty":-2.547433,"marketCap":99376596},{"date":"2022-05-13","current":-1.14627,"twenty":-5.655644,"median":-4.188632,"eighty":-2.530108,"marketCap":92258714},{"date":"2022-05-20","current":-0.816335,"twenty":-5.654821,"median":-4.133519,"eighty":-2.502678,"marketCap":65703535},{"date":"2022-05-27","current":-1.102052,"twenty":-5.652774,"median":-3.930511,"eighty":-2.265187,"marketCap":88699772},{"date":"2022-06-03","current":-0.945588,"twenty":-5.649828,"median":-3.790392,"eighty":-1.806807,"marketCap":76106594},{"date":"2022-06-10","current":-1.017017,"twenty":-5.638325,"median":-3.710388,"eighty":-1.458346,"marketCap":81855654},{"date":"2022-06-17","current":-0.70749,"twenty":-5.619943,"median":-3.662386,"eighty":-1.354377,"marketCap":56943063},{"date":"2022-06-24","current":-0.812934,"twenty":-5.619943,"median":-3.598384,"eighty":-1.267697,"marketCap":65429770},{"date":"2022-07-01","current":-0.979602,"twenty":-5.563744,"median":-3.523713,"eighty":-1.159876,"marketCap":78844242},{"date":"2022-07-08","current":-1.17008,"twenty":-5.533214,"median":-3.456155,"eighty":-1.140148,"marketCap":94175067},{"date":"2022-07-15","current":-1.037426,"twenty":-5.49998,"median":-3.32776,"eighty":-1.085725,"marketCap":83498242},{"date":"2022-07-22","current":-1.057834,"twenty":-5.470823,"median":-3.149101,"eighty":-1.083005,"marketCap":85140831},{"date":"2022-07-29","current":-0.986405,"twenty":-5.364184,"median":-2.77554,"eighty":-1.046269,"marketCap":79391771},{"date":"2022-08-05","current":-1.102052,"twenty":-5.320424,"median":-2.696136,"eighty":-1.036746,"marketCap":88699772},{"date":"2022-08-12","current":-0.822578,"twenty":-5.273125,"median":-2.638387,"eighty":-1.029943,"marketCap":67383911},{"date":"2022-08-19","current":-0.792483,"twenty":-5.1885,"median":-2.582443,"eighty":-1.019739,"marketCap":64918646},{"date":"2022-08-26","current":-0.752358,"twenty":-5.16432,"median":-2.558983,"eighty":-0.995929,"marketCap":61631626},{"date":"2022-09-02","current":-0.692169,"twenty":-5.154364,"median":-2.548154,"eighty":-0.989126,"marketCap":56701096},{"date":"2022-09-09","current":-0.919548,"twenty":-5.147964,"median":-2.539131,"eighty":-0.97416,"marketCap":75327543},{"date":"2022-09-16","current":-1.003143,"twenty":-5.130186,"median":-2.530108,"eighty":-0.962595,"marketCap":82175502},{"date":"2022-09-23","current":-1.003143,"twenty":-5.105296,"median":-2.513866,"eighty":-0.964636,"marketCap":82175502},{"date":"2022-09-30","current":-0.973049,"twenty":-5.093206,"median":-2.475969,"eighty":-0.964636,"marketCap":79710236},{"date":"2022-10-07","current":-0.916204,"twenty":-5.08965,"median":-2.286481,"eighty":-0.962595,"marketCap":75053625},{"date":"2022-10-14","current":-0.769077,"twenty":-5.06476,"median":-1.858781,"eighty":-0.94028,"marketCap":63001218},{"date":"2022-10-21","current":-0.728951,"twenty":-5.046982,"median":-1.5525,"eighty":-0.91821,"marketCap":59714198},{"date":"2022-10-28","current":-0.782452,"twenty":-5.007158,"median":-1.454542,"eighty":-0.886404,"marketCap":64096891},{"date":"2022-11-04","current":-0.765733,"twenty":-4.979423,"median":-1.388688,"eighty":-0.850349,"marketCap":62727299},{"date":"2022-11-11","current":-0.800435,"twenty":-4.969467,"median":-1.311037,"eighty":-0.824584,"marketCap":68402762},{"date":"2022-11-18","current":-0.830646,"twenty":-4.957378,"median":-1.265891,"eighty":-0.82124,"marketCap":70984515},{"date":"2022-11-25","current":-0.849568,"twenty":-4.938888,"median":-1.206298,"eighty":-0.820572,"marketCap":72601537},{"date":"2022-12-02","current":-0.779332,"twenty":-4.887686,"median":-1.17008,"eighty":-0.816068,"marketCap":66599372},{"date":"2022-12-09","current":-0.737639,"twenty":-4.841462,"median":-1.144569,"eighty":-0.808598,"marketCap":63036442},{"date":"2022-12-16","current":-0.750468,"twenty":-4.837906,"median":-1.129263,"eighty":-0.802075,"marketCap":64132728},{"date":"2022-12-23","current":-0.753675,"twenty":-4.830083,"median":-1.115833,"eighty":-0.793821,"marketCap":64406800},{"date":"2022-12-30","current":-0.862717,"twenty":-4.811594,"median":-1.102052,"eighty":-0.792483,"marketCap":73725230},{"date":"2023-01-06","current":-0.871537,"twenty":-4.77177,"median":-1.090148,"eighty":-0.792483,"marketCap":74478927},{"date":"2023-01-13","current":-0.853096,"twenty":-4.74688,"median":-1.061235,"eighty":-0.792483,"marketCap":72903016},{"date":"2023-01-20","current":-0.894789,"twenty":-4.74119,"median":-1.053301,"eighty":-0.795158,"marketCap":76465945},{"date":"2023-01-27","current":-1.372651,"twenty":-4.688566,"median":-1.055567,"eighty":-0.795827,"marketCap":117302597},{"date":"2023-02-03","current":-1.16098,"twenty":-4.613185,"median":-1.081644,"eighty":-0.799513,"marketCap":99213879},{"date":"2023-02-10","current":-0.962138,"twenty":-4.577628,"median":-1.082826,"eighty":-0.801513,"marketCap":82221447},{"date":"2023-02-17","current":-1.148152,"twenty":-4.515758,"median":-1.061235,"eighty":-0.802368,"marketCap":98117593},{"date":"2023-02-24","current":-1.122495,"twenty":-4.501535,"median":-1.084009,"eighty":-0.802643,"marketCap":95925021},{"date":"2023-03-03","current":-0.945045,"twenty":-4.362862,"median":-1.082826,"eighty":-0.804607,"marketCap":83373763},{"date":"2023-03-10","current":-0.864219,"twenty":-4.26828,"median":-1.057834,"eighty":-0.807261,"marketCap":76243112},{"date":"2023-03-17","current":-0.913958,"twenty":-4.219922,"median":-1.04933,"eighty":-0.8088,"marketCap":80631205},{"date":"2023-03-24","current":-0.95748,"twenty":-4.169431,"median":-1.040827,"eighty":-0.809202,"marketCap":84470786},{"date":"2023-03-31","current":-0.985458,"twenty":-4.145964,"median":-1.035725,"eighty":-0.811441,"marketCap":86939088},{"date":"2023-04-06","current":-0.935719,"twenty":-4.134585,"median":-1.030623,"eighty":-0.814116,"marketCap":82550995},{"date":"2023-04-14","current":-1.032089,"twenty":-4.106851,"median":-1.030623,"eighty":-0.816068,"marketCap":91052925},{"date":"2023-04-21","current":-0.917067,"twenty":-4.017114,"median":-1.026546,"eighty":-0.816335,"marketCap":80905461},{"date":"2023-04-28","current":-0.948646,"twenty":-3.911443,"median":-1.02382,"eighty":-0.817495,"marketCap":83691451},{"date":"2023-05-05","current":-0.911322,"twenty":-3.845861,"median":-1.021746,"eighty":-0.820572,"marketCap":80398672},{"date":"2023-05-12","current":-0.980924,"twenty":-3.781858,"median":-1.017017,"eighty":-0.823915,"marketCap":87807424},{"date":"2023-05-19","current":-0.962532,"twenty":-3.746301,"median":-1.012271,"eighty":-0.827811,"marketCap":86161034},{"date":"2023-05-26","current":-0.94108,"twenty":-3.710744,"median":-1.010214,"eighty":-0.834494,"marketCap":84240763},{"date":"2023-06-02","current":-0.892033,"twenty":-3.707189,"median":-1.007219,"eighty":-0.840742,"marketCap":79850365},{"date":"2023-06-09","current":-0.921155,"twenty":-3.693676,"median":-1.004815,"eighty":-0.843978,"marketCap":82457163},{"date":"2023-06-16","current":-0.836856,"twenty":-3.65883,"median":-1.003143,"eighty":-0.837538,"marketCap":74911167},{"date":"2023-06-23","current":-0.833791,"twenty":-3.644608,"median":-0.99838,"eighty":-0.836856,"marketCap":74636767},{"date":"2023-06-30","current":-0.82766,"twenty":-3.607629,"median":-0.996609,"eighty":-0.830049,"marketCap":74087967},{"date":"2023-07-07","current":-0.78781,"twenty":-3.566382,"median":-0.993208,"eighty":-0.824593,"marketCap":70520769},{"date":"2023-07-14","current":-0.815398,"twenty":-3.536514,"median":-0.99316,"eighty":-0.822592,"marketCap":72990368},{"date":"2023-07-21","current":-0.842987,"twenty":-3.522291,"median":-0.989806,"eighty":-0.82124,"marketCap":75459967},{"date":"2023-07-28","current":-0.849118,"twenty":-3.486734,"median":-0.985931,"eighty":-0.822592,"marketCap":76008766},{"date":"2023-08-04","current":-0.842987,"twenty":-3.454022,"median":-0.985458,"eighty":-0.822602,"marketCap":75459967},{"date":"2023-08-11","current":-0.873641,"twenty":-3.441984,"median":-0.980924,"eighty":-0.823797,"marketCap":78203965},{"date":"2023-08-18","current":-0.878604,"twenty":-3.372515,"median":-0.979241,"eighty":-0.82539,"marketCap":74028579},{"date":"2023-08-25","current":-0.940627,"twenty":-3.299607,"median":-0.975457,"eighty":-0.826964,"marketCap":79254417},{"date":"2023-09-01","current":-0.937361,"twenty":-3.233197,"median":-0.973023,"eighty":-0.82766,"marketCap":78979228},{"date":"2023-09-08","current":-0.885104,"twenty":-3.159567,"median":-0.971728,"eighty":-0.82766,"marketCap":74576205},{"date":"2023-09-15","current":-0.829581,"twenty":-2.981269,"median":-0.970062,"eighty":-0.826617,"marketCap":69897993},{"date":"2023-09-22","current":-0.76426,"twenty":-2.79503,"median":-0.966806,"eighty":-0.822588,"marketCap":64394214},{"date":"2023-09-29","current":-0.70547,"twenty":-2.766156,"median":-0.965603,"eighty":-0.816906,"marketCap":59440813},{"date":"2023-10-06","current":-0.646681,"twenty":-2.727897,"median":-0.962595,"eighty":-0.815979,"marketCap":54487412},{"date":"2023-10-13","current":-0.604222,"twenty":-2.71346,"median":-0.962532,"eighty":-0.812453,"marketCap":50909955},{"date":"2023-10-20","current":-0.636883,"twenty":-2.666539,"median":-0.960045,"eighty":-0.808397,"marketCap":53661845},{"date":"2023-10-27","current":-0.679342,"twenty":-2.665096,"median":-0.95957,"eighty":-0.806065,"marketCap":57239301},{"date":"2023-11-03","current":-0.816517,"twenty":-2.648493,"median":-0.95748,"eighty":-0.802222,"marketCap":68797237},{"date":"2023-11-10","current":-0.522571,"twenty":-2.614566,"median":-0.947902,"eighty":-0.798373,"marketCap":44030232},{"date":"2023-11-17","current":-0.442347,"twenty":-2.594354,"median":-0.946599,"eighty":-0.792483,"marketCap":35925248},{"date":"2023-11-24","current":-0.401672,"twenty":-2.584248,"median":-0.945588,"eighty":-0.790684,"marketCap":32621777},{"date":"2023-12-01","current":-0.305101,"twenty":-2.570532,"median":-0.942446,"eighty":-0.788267,"marketCap":24778786},{"date":"2023-12-08","current":-0.311846,"twenty":-2.563314,"median":-0.941074,"eighty":-0.783066,"marketCap":25326611},{"date":"2023-12-15","current":-0.247443,"twenty":-2.556095,"median":-0.940627,"eighty":-0.780271,"marketCap":20096115},{"date":"2023-12-22","current":-0.180091,"twenty":-2.551764,"median":-0.938014,"eighty":-0.774301,"marketCap":14626118},{"date":"2023-12-29","current":-0.193209,"twenty":-2.551764,"median":-0.937361,"eighty":-0.770792,"marketCap":15691487},{"date":"2024-01-05","current":-0.245647,"twenty":-2.547433,"median":-0.936267,"eighty":-0.769457,"marketCap":19950212},{"date":"2024-01-12","current":-0.275645,"twenty":-2.54238,"median":-0.935334,"eighty":-0.766195,"marketCap":22386522},{"date":"2024-01-19","current":-0.233071,"twenty":-2.539492,"median":-0.934949,"eighty":-0.764849,"marketCap":18928889},{"date":"2024-01-26","current":-0.216937,"twenty":-2.534439,"median":-0.93261,"eighty":-0.754249,"marketCap":17618512},{"date":"2024-02-02","current":-0.227106,"twenty":-2.530108,"median":-0.92518,"eighty":-0.752358,"marketCap":18444380},{"date":"2024-02-09","current":-0.203378,"twenty":-2.528664,"median":-0.923284,"eighty":-0.751224,"marketCap":16517355},{"date":"2024-02-16","current":-0.199107,"twenty":-2.525055,"median":-0.920389,"eighty":-0.749014,"marketCap":16170491},{"date":"2024-02-23","current":-0.18643,"twenty":-2.519281,"median":-0.919085,"eighty":-0.746197,"marketCap":15140909},{"date":"2024-03-01","current":-0.240325,"twenty":-2.504121,"median":-0.917067,"eighty":-0.739651,"marketCap":19518008},{"date":"2024-03-08","current":-0.270832,"twenty":-2.496181,"median":-0.915351,"eighty":-0.735638,"marketCap":21995611},{"date":"2024-03-15","current":-0.219174,"twenty":-2.466585,"median":-0.913491,"eighty":-0.731225,"marketCap":17800203},{"date":"2024-03-22","current":-0.238122,"twenty":-2.421829,"median":-0.911599,"eighty":-0.715205,"marketCap":19339070},{"date":"2024-03-28","current":-0.216598,"twenty":-2.392955,"median":-0.911029,"eighty":-0.70547,"marketCap":17590983},{"date":"2024-04-05","current":-0.545745,"twenty":-2.180008,"median":-0.910426,"eighty":-0.68914,"marketCap":41697098},{"date":"2024-04-12","current":-0.613532,"twenty":-2.057292,"median":-0.907037,"eighty":-0.679342,"marketCap":46876301},{"date":"2024-04-19","current":-0.577442,"twenty":-1.858781,"median":-0.904632,"eighty":-0.663875,"marketCap":44118872},{"date":"2024-04-26","current":-0.455638,"twenty":-1.793814,"median":-0.901286,"eighty":-0.653213,"marketCap":34812547},{"date":"2024-05-03","current":-0.507198,"twenty":-1.570039,"median":-0.897996,"eighty":-0.636883,"marketCap":38751930},{"date":"2024-05-10","current":-0.608637,"twenty":-1.534961,"median":-0.892115,"eighty":-0.623819,"marketCap":46502316},{"date":"2024-05-17","current":-0.561705,"twenty":-1.473562,"median":-0.887764,"eighty":-0.608637,"marketCap":39859128},{"date":"2024-05-24","current":-0.556504,"twenty":-1.454542,"median":-0.885503,"eighty":-0.604222,"marketCap":39490062},{"date":"2024-05-31","current":-0.483742,"twenty":-1.448767,"median":-0.881558,"eighty":-0.597071,"marketCap":34326828},{"date":"2024-06-07","current":-0.53057,"twenty":-1.404749,"median":-0.876706,"eighty":-0.586439,"marketCap":37649763},{"date":"2024-06-14","current":-0.546175,"twenty":-1.387604,"median":-0.876079,"eighty":-0.580482,"marketCap":38757109},{"date":"2024-06-21","current":-0.496031,"twenty":-1.379022,"median":-0.873673,"eighty":-0.570621,"marketCap":35198837},{"date":"2024-06-28","current":-0.488956,"twenty":-1.374775,"median":-0.873641,"eighty":-0.569679,"marketCap":34696841},{"date":"2024-07-05","current":-0.448904,"twenty":-1.357353,"median":-0.873641,"eighty":-0.561773,"marketCap":31854652},{"date":"2024-07-12","current":-0.520114,"twenty":-1.333588,"median":-0.87282,"eighty":-0.555857,"marketCap":36907841},{"date":"2024-07-15","current":-0.53057,"twenty":-1.329066,"median":-0.872339,"eighty":-0.554184,"marketCap":37649763},{"date":"2024-08-02","current":-0.494158,"twenty":-1.324544,"median":-0.872339,"eighty":-0.551376,"marketCap":35065956},{"date":"2024-08-09","current":-0.483847,"twenty":-1.311037,"median":-0.871537,"eighty":-0.546175,"marketCap":31707006},{"date":"2024-08-16","current":-0.556692,"twenty":-1.27492,"median":-0.868973,"eighty":-0.546175,"marketCap":36480567},{"date":"2024-08-23","current":-0.597874,"twenty":-1.27323,"median":-0.865924,"eighty":-0.546175,"marketCap":39179250},{"date":"2024-08-30","current":-0.538985,"twenty":-1.267697,"median":-0.863468,"eighty":-0.546175,"marketCap":35320221},{"date":"2024-09-06","current":-0.518595,"twenty":-1.264807,"median":-0.862048,"eighty":-0.54616,"marketCap":33984066},{"date":"2024-09-13","current":-0.549985,"twenty":-1.263703,"median":-0.858314,"eighty":-0.545667,"marketCap":36041042},{"date":"2024-09-20","current":-0.524699,"twenty":-1.232207,"median":-0.857152,"eighty":-0.544779,"marketCap":34384033},{"date":"2024-09-27","current":-0.504376,"twenty":-1.201879,"median":-0.854893,"eighty":-0.540606,"marketCap":33052273},{"date":"2024-10-04","current":-0.486602,"twenty":-1.189844,"median":-0.850349,"eighty":-0.531977,"marketCap":31887532},{"date":"2024-10-11","current":-0.528522,"twenty":-1.186983,"median":-0.849328,"eighty":-0.53057,"marketCap":34634562},{"date":"2024-10-18","current":-0.529863,"twenty":-1.186643,"median":-0.84452,"eighty":-0.530429,"marketCap":34722467},{"date":"2024-10-25","current":-0.62108,"twenty":-1.173809,"median":-0.842987,"eighty":-0.530429,"marketCap":40700006},{"date":"2024-10-31","current":-0.918877,"twenty":-1.170289,"median":-0.84264,"eighty":-0.53057,"marketCap":60214912},{"date":"2024-11-08","current":-0.727841,"twenty":-1.17008,"median":-0.842987,"eighty":-0.53057,"marketCap":45710590},{"date":"2024-11-15","current":-0.669964,"twenty":-1.168468,"median":-0.840267,"eighty":-0.53057,"marketCap":42075719},{"date":"2024-11-22","current":-0.643941,"twenty":-1.163546,"median":-0.839921,"eighty":-0.531625,"marketCap":40441428},{"date":"2024-11-29","current":-0.76293,"twenty":-1.160538,"median":-0.835323,"eighty":-0.532657,"marketCap":47914300},{"date":"2024-12-06","current":-0.734933,"twenty":-1.159035,"median":-0.830725,"eighty":-0.534491,"marketCap":46155977},{"date":"2024-12-13","current":-0.720934,"twenty":-1.15649,"median":-0.82862,"eighty":-0.53653,"marketCap":45276816},{"date":"2024-12-20","current":-0.65654,"twenty":-1.152,"median":-0.82766,"eighty":-0.53657,"marketCap":41232673},{"date":"2024-12-27","current":-0.682437,"twenty":-1.147776,"median":-0.825921,"eighty":-0.53657,"marketCap":42859122},{"date":"2025-01-03","current":-0.748931,"twenty":-1.14627,"median":-0.822602,"eighty":-0.53657,"marketCap":47035139},{"date":"2025-01-10","current":-0.783928,"twenty":-1.145209,"median":-0.822578,"eighty":-0.537107,"marketCap":49233042},{"date":"2025-01-17","current":-0.797927,"twenty":-1.143284,"median":-0.817491,"eighty":-0.538636,"marketCap":50112204},{"date":"2025-01-24","current":-0.580737,"twenty":-1.142869,"median":-0.816517,"eighty":-0.540201,"marketCap":36472013},{"date":"2025-01-31","current":-0.486385,"twenty":-1.140266,"median":-0.816335,"eighty":-0.53657,"marketCap":30546465},{"date":"2025-02-07","current":-0.482956,"twenty":-1.13297,"median":-0.815659,"eighty":-0.532822,"marketCap":30331071},{"date":"2025-02-14","current":-0.902917,"twenty":-1.125202,"median":-0.815429,"eighty":-0.53057,"marketCap":56705915},{"date":"2025-02-21","current":-0.771637,"twenty":-1.122495,"median":-0.815398,"eighty":-0.531274,"marketCap":48461135},{"date":"2025-02-28","current":-0.649413,"twenty":-1.121121,"median":-0.810785,"eighty":-0.532657,"marketCap":40785074},{"date":"2025-03-07","current":-0.678968,"twenty":-1.117838,"median":-0.809202,"eighty":-0.534491,"marketCap":42641227},{"date":"2025-03-14","current":-0.710276,"twenty":-1.115867,"median":-0.80603,"eighty":-0.53653,"marketCap":41367199},{"date":"2025-03-21","current":-0.696942,"twenty":-1.110216,"median":-0.804926,"eighty":-0.53657,"marketCap":40590594},{"date":"2025-03-28","current":-0.648849,"twenty":-1.102052,"median":-0.802148,"eighty":-0.53657,"marketCap":37789636},{"date":"2025-04-04","current":-0.622447,"twenty":-1.09797,"median":-0.800186,"eighty":-0.536838,"marketCap":36251956},{"date":"2025-04-11","current":-0.588045,"twenty":-1.090488,"median":-0.797927,"eighty":-0.537939,"marketCap":34248313},{"date":"2025-04-17","current":-0.67374,"twenty":-1.087559,"median":-0.796877,"eighty":-0.53939,"marketCap":39239300},{"date":"2025-04-21","current":-0.66814,"twenty":-1.086672,"median":-0.795827,"eighty":-0.539795,"marketCap":38913125}],"updateTime":1745374100436}}}